Physicochemical Properties
| Molecular Formula | C21H32O3 |
| Molecular Weight | 332.4770 |
| Exact Mass | 332.235 |
| CAS # | 36752-54-2 |
| PubChem CID | 6442612 |
| Appearance | Colorless to light yellow liquid |
| LogP | 5.599 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 13 |
| Heavy Atom Count | 24 |
| Complexity | 351 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C(C([H])([H])C([H])([H])C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])O[H])/C(/[H])=C(\[H])/C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] |
| InChi Key | FADFGCOCHHNRHF-VAWYXSNFSA-N |
| InChi Code | InChI=1S/C21H32O3/c1-3-4-5-6-7-8-9-10-11-12-19(22)15-13-18-14-16-20(23)21(17-18)24-2/h11-12,14,16-17,23H,3-10,13,15H2,1-2H3/b12-11+ |
| Chemical Name | (E)-1-(4-hydroxy-3-methoxyphenyl)tetradec-4-en-3-one |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets |
- Cyclooxygenase-2 (COX-2): [10]-Shogaol inhibits COX-2 activity with an IC50 of 2.7 μM; it shows no significant inhibition on COX-1 (IC50 > 100 μM), indicating high selectivity for COX-2 [2] - Drug resistance-related transporters (ABCG2, MRP1): [10]-Shogaol downregulates the expression of these transporters in docetaxel-resistant prostate cancer cells[3] |
| ln Vitro |
- Skin cell proliferation and migration promotion [1] - On HaCaT human keratinocytes: [10]-Shogaol (1 μM, 5 μM, 10 μM) increased cell proliferation by 15%, 32%, and 45% respectively (48 h, MTT assay) vs. control. In the scratch wound healing assay, 5 μM [10]-Shogaol accelerated wound closure rate by 58% at 24 h and 72% at 48 h vs. control. - Antioxidant activity: It scavenged DPPH radicals with an EC50 of 8.3 μM and ABTS radicals with an EC50 of 6.1 μM. It also reduced H₂O₂-induced intracellular ROS levels in HaCaT cells by 42% (5 μM, 2 h treatment) [1] - COX-2 inhibitory activity [2] - In a cell-free COX-2 assay: [10]-Shogaol (0.1–10 μM) inhibited COX-2-mediated prostaglandin E2 (PGE2) production in a dose-dependent manner. At 5 μM, it reduced PGE2 levels by 89% vs. the enzyme-only control [2] - Antiproliferative and drug resistance-modulating activity in prostate cancer cells [3] - On docetaxel-resistant DU145 (DU145/DocR) cells: [10]-Shogaol inhibited proliferation with an IC50 of 12.5 μM (72 h, MTT assay). It downregulated the expression of ABCG2 (protein level reduced by 65% at 10 μM) and MRP1 (protein level reduced by 58% at 10 μM) via western blot. It also sensitized DU145/DocR cells to docetaxel, reducing the docetaxel IC50 from 80 nM to 22 nM (10 μM [10]-Shogaol pretreatment) [3] |
| Enzyme Assay |
- Reaction system preparation: The assay mixture (200 μL total volume) contained 50 mM Tris-HCl buffer (pH 8.0), 1 μM heme, 100 μM arachidonic acid (substrate), recombinant human COX-2 enzyme, and serial dilutions of [10]-Shogaol (0.1–10 μM). The control group lacked [10]-Shogaol. - Incubation and detection: The mixture was incubated at 37°C for 15 minutes to allow PGE2 synthesis. The reaction was terminated by adding 5 μL of 1 M HCl. PGE2 concentration was measured using a competitive ELISA kit, with absorbance read at 450 nm. The IC50 was calculated by fitting the dose-response curve of PGE2 inhibition [2] |
| Cell Assay |
- HaCaT cell proliferation and migration assays [1] - Proliferation assay (MTT): HaCaT cells were seeded in 96-well plates (5×10³ cells/well) and incubated overnight. [10]-Shogaol (0.5–20 μM) was added, and cells were incubated for 24 h/48 h. MTT reagent was added, incubated for 4 h, formazan dissolved in DMSO, and absorbance measured at 570 nm. Proliferation rate was calculated vs. control. - Wound healing assay: HaCaT cells were seeded in 6-well plates and grown to 100% confluence. A scratch was made with a pipette tip; [10]-Shogaol (1–10 μM) was added. Images were taken at 0 h, 24 h, 48 h, and wound closure rate was calculated as [(initial wound width – final wound width)/initial wound width] × 100% [1] - DU145/DocR prostate cancer cell assays [3] - Proliferation assay (MTT): DU145/DocR cells were seeded in 96-well plates (3×10³ cells/well) and treated with [10]-Shogaol (2.5–40 μM) for 72 h. MTT assay was performed as above to calculate IC50. - Drug resistance factor detection (western blot): Cells were treated with [10]-Shogaol (5 μM, 10 μM) for 48 h, lysed with RIPA buffer. Equal amounts of protein were separated by SDS-PAGE, transferred to PVDF membranes, and probed with anti-ABCG2 and anti-MRP1 antibodies. Band intensity was quantified vs. GAPDH (loading control) [3] |
| References |
[1]. 10-Shogaol, an antioxidant from Zingiber officinale for skin cell proliferation and migration enhancer. Int J Mol Sci. 2012;13(2):1762-77. [2]. Cyclooxygenase-2 inhibitors in ginger (Zingiber officinale). Fitoterapia. 2011 Jan;82(1):38-43. [3]. Ginger Phytochemicals Inhibit Cell Growth and Modulate Drug Resistance Factors in Docetaxel Resistant Prostate Cancer Cell. Molecules. 2017 Sep 5;22(9). pii: E1477. |
| Additional Infomation |
[10]-Shogaol is a monomethoxybenzene, a member of phenols and an enone. [10]-Shogaol has been reported in Zingiber officinale with data available. See also: Ginger (part of). - [10]-Shogaol is a bioactive phenol derived from the rhizome of Zingiber officinale (ginger), formed by dehydration of [6]-gingerol during ginger processing (e.g., drying, heating) [1,2,3] - Mechanisms of action: [1] Antioxidant activity via scavenging free radicals (DPPH/ABTS) and reducing intracellular ROS; promotes HaCaT cell migration possibly by activating the ERK1/2 signaling pathway (phospho-ERK1/2 upregulated by 2.3-fold at 5 μM). [2] Selective COX-2 inhibition by binding to the enzyme’s active site, blocking arachidonic acid conversion to PGE2. [3] Sensitizes docetaxel-resistant prostate cancer cells by downregulating ABCG2/MRP1 (ATP-binding cassette transporters that efflux chemotherapeutics) [1,2,3] |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~300.77 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.52 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0077 mL | 15.0385 mL | 30.0770 mL | |
| 5 mM | 0.6015 mL | 3.0077 mL | 6.0154 mL | |
| 10 mM | 0.3008 mL | 1.5038 mL | 3.0077 mL |